Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896629 | 0.94 | APP (0.35) | APPMAPTTSHR | |
| SCHEMBL4896498 | 0.88 | APP (0.38) | APP | |
| SCHEMBL7983449 | 0.81 | APP (0.41) | APPCYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL7983453 | 0.81 | APP (0.41) | APPCYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL15051242 | 0.81 | APP (0.41) | APPCYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL30375126 | 0.81 | APP (0.41) | APPCYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL4894976 | 0.81 | APP (0.41) | APPTSHRALDH1A1 | |
| SCHEMBL1611320 | 0.78 | TSHR (0.45) | MAPTCYP2D6TSHRALDH1A1 | |
| SCHEMBL4890465 | 0.76 | NFE2L2 (0.46) | ALDH1A1 | |
| SCHEMBL15563320 | 0.76 | POLB (0.37) | CYP3A4CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC | 2008-08-14 | — | — | US | disclosed |
| EP-1869051-A1 | 4-PIPERAZINYLTHIENO Ý2,3-D¨PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006103545-A1 | 4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFKP, PF4, P2RY4 | APP 4234/4885MAPT 4491/4885CYP3A4 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.